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Abstract
Background: This study aimed at developing nerve growth factor (NGF) mimetics that selectively activate specific
biological signals and, as a result, lack the side effects of the full-length protein. Two dimeric dipeptides,
bis-(N-aminocaproyl-glycyl-L-lysine) hexamethylenediamide (GK-6) and bis(N-succinyl-L-glutamyl-L-lysine)
hexamethylenediamide (GK-2), were designed based on the most exposed outside fragments of NGF, namely, the
loop 1 and loop 4 β-turn sequences, respectively. These dipeptides exhibited neuroprotective activity in vitro at
micro-nanomolar concentrations.
Results: Studies on the mechanism of action revealed that both compounds elevate the level of tyrosine kinase A (TrkA)
receptor phosphorylation and that they each have different postreceptor signaling patterns. GK-6 increases the levels of
extracellular signal-regulated kinase (ERK) and AKT kinase phosphorylation, whereas GK-2 only increases the level of AKT
phosphorylation. Apart from the neuroprotective activity, GK-6 promoted differentiation in PC12 cells, whereas GK-2 did
not. Furthermore, it was established that the neuroprotective activity of GK-2 was completely abolished by a selective
inhibitor of phosphatidylinositol 3-kinase (LY294002) but not by a specific inhibitor of mitogen-activated protein kinases
MEK1 and MEK2 (PD98059). In vivo experiments demonstrated that GK-2 did not induce hyperalgesia, which is one of
the primary adverse effects of NGF. By contrast, GK-6 produced a significant decrease in the pain threshold of rats as
determined by the tail flick test.
Conclusion: The data obtained suggest that dimeric dipeptide NGF mimetics are promising candidates in the
development of pharmacological agents with NGF-like activity that are free of the main side effect of NGF.
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Background
Nerve growth factor (NGF), a member of the neurotrophin
family, is essential for the development and survival of sev-
eral populations of neurons and a number of nonneural
cells. Despite this factor’s considerable therapeutic poten-
tial, the clinical application of NGF is limited by its strong
side effects, the most important of which are hyperalgesia
and weight loss [1].
NGF exerts its main effects by interaction with the
TrkA transmembrane receptor. Activation of TrkA by
NGF triggers signal transduction cascades involving phos-
phatidylinositol 3-kinase/AKT (PI3K/AKT) and mitogen-
activated protein kinase/extracellular-signal-regulated
kinases (MAPK/ERK) pathways. The PI3K/AKT pathway
is involved in the regulation of cell survival but not in the
differentiation and formation of neurites [2]. The MAP-
kinase pathway is associated with neuroprotection and dif-
ferentiation and appears to be involved in hyperalgesia [3].
The design of small, proteolytically stable NGF mimetics
that exert defined biological activities via the selective
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activation of TrkA-mediated signaling might provide a use-
ful approach for the development of therapeutic agents for
several diseases applications [2, 4].
We formed the working hypothesis [5] that by inter-
acting with the same receptor, multiple neurotrophin
hairpin loops can activate various intracellular signal-
ing cascades and are therefore responsible for an array
of neurotrophin effects. Within the framework of this
hypothesis, the dimeric dipeptide bis(N-succinyl-L-
glutamyl-L-lysine) hexamethylenediamide (GK-2) was
designed based on the NGF loop 4 β-turn sequence
Asp93–Glu94–Lys95–Gln96, which is the most exposed
fragment and therefore may play a major role in the inter-
action of NGF with the receptor. We included the central
fragment of the β-turn, Glu94–Lys95, in the dipeptide com-
position. The residue Asp93 was substituted by its bioisos-
tere, a succinic acid residue, and Gln96 was substituted by
an amide group. The purpose of these two substitutions
was to stabilize the β-turn conformation and to increase
the resistance of the compound to peptidases. Because
NGF interacts with the TrkA in the homodimer form, we
linked two β-turn mimetics by a hexamethylene diamine
spacer. The dimeric dipeptide bis-(N-aminocaproyl-
glycyl-L-lysine) hexamethylenediamide (GK-6) was
designed analogously to GK-2 based on the NGF loop
1 β-turn (RU Patent №2410392, 2010; US Patent
Appliction №US 2011/0312895 A1).
It has been shown in vitro, using both immortalized and
primary cell cultures, that GK-2 and GK-6 exert NGF-like
neuroprotective activity (10uM-1nM) [5, 6]. Maximal neu-
roprotective effects were observed at concentrations of
1uМ (GK-6) and 10nМ (GK-2); therefore, these concen-
trations were used for further in vitro experiments.
The neuroprotective activity of GK-2 at doses of 0.1-
1 mg/kg (i.p.) was also determined in animal models of
cerebral ischemia [7, 8] and in a model of rat traumatic
brain injury [9].
Herein, we report a comparative study of the NGF
loop 1 and NGF loop 4 β-turn mimetics, GK-6 and
GK-2, respectively. We established that both peptides
activate TrkA receptors but showed different patterns
of intracellular signal transduction.
Methods
Drugs and reagents
The dimeric dipeptides GK-6 and GK-2 were synthesized
on the base of murine NGF at the Zakusov Institute of
Pharmacology (Moscow, Russia).
Inhibitors of PI3K (LY294002) and MAPK (PD98059)
were purchased from Tocris Bioscience (Bristol, UK).
The tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide (MTT),was obtained from
Sigma-Aldrich (St. Louis, MO, USA). Dulbecco’s Modified
Eagle’s medium was purchased from HyClone Laboratories
(Logan, UT, USA). Fetal bovine serum was obtained from
Gibco (Langley, OK, USA). Glutamine was purchased
from ICN Pharmaceuticals. Inc. (Costa Mesa, CA, USA).
Poly-D-lysine was purchased from BD Biosciences
(San Jose, CA, USA). DC protein assay was purchased
from Biorad (Hercules, CA, USA). Anti-TrkA, anti-pTrkA,
anti-AKT1/2/3, anti-pAKT1/2/3, anti-ERK1/2, anti-pERK1/
2 antibodies and enhanced chemiluminescence kits were
obtained from Santa Cruz Biotechnology (Dallas, TX,
USA). Anti-β-actin antibodies and horseradish peroxidase
conjugated antibodies were purchased from Abcam
(Cambridge, MA, USA).
Cell cultures
Cells were maintained at 37 °C in Dulbecco’s Modified
Eagle’s medium, 10 % fetal bovine serum, 2 mM glu-
tamine, 5 % CO2 and 95 % air at 37 °C and passaged by
trypsinization. Rat hippocampal neurons were taken
from 18-day-old fetuses using techniques previously
described [10]. Cells were placed on 48-well plastic
plates previously treated with poly-D-lysine (5 mkg/
1 cm2) at a plating density of 350x103 cells per well.
The cultures were maintained in a humidified atmos-
phere of 5 % CO2 and 95 % air at 37 °C.
Western blot analysis
The mouse hippocampal HT-22 cells were plated into
6-well plates at 200 x 103 cells per well. Fifteen, 30, 60
and 180 min after incubation with GK-6 (10−6M), GK-
2 (10−8M) or NGF (10−9M) [11], cells were collected,
and protein was extracted for Western blot analysis.
Samples were homogenized in a lysis buffer (50 mM
Tris–HCl, pH = 7.5, 5 mM EDTA, 1 mM DTT, 1 %
Triton X-100 supplemented with protease and phos-
phatase inhibitor cocktail), incubated on ice for 5 min
and then centrifuged (13 000 rpm, 10 min, at 4 °C).
Protein levels of the supernatant lysates were measured
using the DC protein assay. Proteins were separated in a
10 % SDS-PAGE gel and blotted for 1 h (15 V) onto a
PVDF membrane. Membranes were incubated at 4 °C
overnight with the following primary antibodies: anti-
pTrkA, anti-pAKT1/2/3, anti-pERK1/2, anti-TrkA, anti-
ERK1/2, and anti-AKT1/2/3. All of the antibodies were
used at 1:1000 final dilutions in 0.5 % non-fat dry milk in
TBST. Equal loading was confirmed using anti-.-actin
(1:5000 in 0.5 % non-fat dry milk in TBST). Membranes
were washed with TBS/0.5 % Tween (TBST) and incu-
bated with horseradish peroxidase conjugated secondary
antibody (1:20000 in 0.5 % non-fat dry milk in TBST).
Secondary antibodies tagged to peroxidase were used to
visualize immunoreactive bands using enhanced chemilu-
minescence kits.
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Measurement of PC12 cell morphological differentiation
(neurite outgrowth)
NGF mimetics were tested for their ability to induce
neurite outgrowth in PC12 cells. The cells were treated
with GK-6 (10−6M), GK-2 (10−5 and 10−8M) or NGF
(10−9M) 3 times per 48-h time period. An Eclipse
TS100-F light microscope (Nikon, Tokyo, Japan) equipped
with a phase- contrast condenser, a 20X objective lens and
a digital camera (Canon, Tokyo, Japan) was used to cap-
ture images using the manual setting. To analyze the
number and length of neurites, approximately 100 cells
were counted from at least 10 randomly chosen visual
fields for each culture. Using the Photoshop software pro-
gram (Adobe, San Jose, CA, USA), the number and length
of neurites were analyzed. The cells were scored as differ-
entiated if one or more neurites were longer than the
diameter of the cell body.
Cell viability assay
To examine whether GK-2 exerts neuroprotective
activity through AKT signaling, we used LY294002, a
specific inhibitor of PI3K, and the MAPK inhibitor
PD98059. Concentrations of 100 μM and 50 μM were
selected for LY294002 and PD98059, respectively [12, 13].
The hippocampal cells HT-22 were pre-incubated with
LY294002 and PD98059 for 30 min before treatment with
GK-2 (10−5M and 10−8M) or NGF (10−9M) for 24 h. The
cells were then exposed to oxidative stress (1.5 mM H2O2
for 30 min) [14], and cell survival after 30 min was mea-
sured at 37 °C using the MTTassay [15].
Animals
Both male Wistar rats (300–380 g) and outbred rats
(250–300 g) were purchased from the Animal Breeding
Facility at the Institute of Bioorganic Chemistry in Push-
chino (Moscow, Russia). The animals were housed under
natural light–dark cycling conditions with food and water
provided ad libitum. All experimental procedures were
performed in accordance with the requirements of the
Directive 2010/63EU of the European Parliament and the
Council of 22 September 2010 on the protection of animals
used for scientific purposes and were approved by the
Fig. 1 Western blot analysis of TrkA phosphorylation in HT-22 hippocampal neurons at different times (15, 30, 60 and 180 min) after incubation
with GK-6 (10-6M), GK-2 (10-8M) or NGF (10-9M). Results were calculated as the ratio of arbitrary densitometric units of phosphorylated target
protein to total non-phosphorylated target protein. Total nonphosphorylated target protein arbitrary densitometric units were analyzed separately
against β-actin. Data are presented as means±SD of five independent experiments. Differences from the control were significant at *-р < 0.05
(Mann–Whitney U test)
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Institutional Animal Care and Use Committee of Zakusov
Institute of Pharmacology (Meeting Protocol №1 from
10.11.2014).
Tail flick test
In two separate experiments with GK-6 and GK-2, 36
and 40 male outbred rats were used, respectively. In
these groups, each control or experimental subgroup
was composed of 9–10 animals. The experiments were
performed from 5 to 8 p.m. The effects of peptides on
the pain thresholds were assessed via the immersion “tail
flick” test in rats [16]. The animals were habituated to indi-
vidual Plexiglas cylindrical restrainers for 20–30 min. Next,
thermal noxious stimuli were applied by immersing the dis-
tal third of each rat's tail in hot water (55 ± 0.2 °C), and the
latencies of reflex were measured. Dipeptides GK-6 and
GK-2 dissolved in distilled water were administered i.p. at
doses of 0.5, 1.0 and 2.0 mg/kg. Control animals were
injected with an equal volume of vehicle. Tail flick latency
was measured 3–4 times for 30 min in 10-min intervals
before GK-6 or GK-2 administration (the mean baseline
level) and 30, 60 min and 24 h after dipeptide administra-
tion. The time intervals were selected based on data related
to NGF-induced hyperalgesia [17]. The cutoff time for
latencies was set to 20 s to avoid skin damage.
The study of possible effects of GK-2 and GK-6 on the
body weight of rats
Male Wistar rats were used. Separate experiments were
performed with GK-6 and GK-2. In each experiment, the
rats were randomly assigned to the following two groups:
the control group (n = 10) and the GK-6 group (n = 10) in
the first experiment and the control group (n = 12) and the
GK-2 group (n = 13) in the second experiment. GK-6 and
GK-2 (dissolved in distilled water) were administered daily
at doses of 2 mg/kg and 0.5 mg/kg i.p., respectively, for
2 weeks. These doses were chosen as the most pharmaco-
logically active doses based on preliminary studies. Control
animals received i.p. injections of distilled water. The body
weight of the rats was measured every 3–4 days during the
experiment.
Statistical methods and data analysis
Kruskal-Wallis ANOVA followed by Dunn’s post test was
used to compare three or more samples. The Mann–
Whitney U test was used to compare the differences
between two independent groups. The data are presented
as means ± standard deviation (SD) or as means ± stand-
ard error of mean (SEM). P-values <0.05 were considered
significant.
Fig. 2 Western blot analysis of AKT 1/2/3 phosphorylation in HT-22 hippocampal neurons at different times (15, 30, 60 and 180 min) after incubation
with GK-6 (10-6M), GK-2 (10-8M) or NGF (10-9M). Results were calculated as the ratio of arbitrary densitometric units of phosphorylated target protein to
total non-phosphorylated target protein. Total nonphosphorylated target protein arbitrary densitometric units were analyzed separately against β-actin.
Data are presented as means±SD of five independent experiments. Differences from the control were significant at *-р < 0.05 (Mann–Whitney U test)
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Results
Both dipeptides, GK-6 and GK-2, activate TrkA receptors
The dipeptides GK-6 (10−6M) and GK-2 (10−8M) added
to HT-22 hippocampal neurons induced the elevation of
TrkA receptor phosphorylation after incubation for 15,
30, 60 and 180 min, similarly to NGF (10−9M) (Fig. 1).
GK-6 and GK-2 exhibit different patterns of PI3K/AKT and
MAPK/ERK activation
ERK activation and AKT activation by GK-6 and GK-2
were assessed using the ERK1/2 and AKT1/2/3 phos-
phorylation assays. Western blot densitometry analysis
revealed that AKT1/2/3 phosphorylation was increased
after stimulation of the cells by GK-6 (10−6M), GK-2
(10−8M) or NGF (10−9M) at the time intervals observed
for TrkA (i.e., 15, 30, 60, and 180 min incubations)
(Fig. 2). GK-6 and NGF induced phosphorylation of
ERK1/2. There was no activation of ERK1/2 proteins by
GK-2 at any time point (Fig. 3). These data suggest that
GK-2 selectively activates PI3K/AKT signaling, whereas
GK-6 activates both the PI3K/AKT and MAPK/ERK
pathways.
GK-6 induces the differentiation of PC12 cells
It was established that GK-6 (10−6M) and NGF (10−9M)
induced neurite outgrowth in PC12 cells, whereas GK-2
(10−5 and 10−8M) had no effect (Fig. 4). These findings
are consistent with previous studies demonstrating that
GK-6 activates the MAPK/ERK signaling pathway involved
in cell differentiation, whereas GK-2 selectively activates the
PI3K/AKT pathway.
LY294002, a selective inhibitor of PI3K, fully abolishes the
neuroprotective activity of GK-2
To confirm the involvement of the PI3K/AKT pathway in
the neuroprotective effects of GK-2, we pretreated HT22
cells with LY294002 (a selective inhibitor of PI3K) or
PD98059 (a specific inhibitor of MAPK) followed by GK-2
or NGF and then H2O2. As shown in Fig. 5, compound
LY294002 fully blocked the neuroprotective effects of both
NGF and GK-2. Under the same conditions, PD98059 had
practically no effect on the development of the neuro-
protective action of GK-2 and partly abolished the
neuroprotective effect of NGF (Fig. 6). These results
indicate that GK-2 enhances cell survival through the
Figs. 3 Western blot analysis of ERK 1/2 phosphorylation in HT-22 hippocampal neurons at different times (15, 30, 60 and 180 min) after incubation
with GK-6 (10-6M), GK-2 (10-8M) or NGF (10-9M). Results were calculated as the ratio of arbitrary densitometric units of phosphorylated target protein to
total non-phosphorylated target protein. Total nonphosphorylated target protein arbitrary densitometric units were analyzed separately against β-actin.
Data are presented as means±SD of five independent experiments. Differences from the control were significant at *-р < 0.05 (Mann–Whitney U test)
Gudasheva et al. Journal of Biomedical Science  (2015) 22:106 Page 5 of 10
increased activation of the PI3K/AKT pathway. Inter-
estingly, LY294002 almost fully prevented the neuro-
protective action of NGF, whereas PD98059 only
partially prevented the neuroprotection. These results
can be explained by the data indicating that NGF-
mediated survival is associated mainly with the PI3K/
AKT pathway and, to a much lower extent, with
MAPK/ERK signaling [2].
Different effects of GK-6 and GK-2 on pain sensitivity in rats
The dipeptide GK-6 at a dose of 2.0 mg/kg significantly
decreased the pain threshold at 1 h (by 30.0 %) and 24 h
(by 38.0 %) after injection compared to the control
group (Fig. 7a). As shown in Fig. 7b, GK-2 at all doses
tested did not have any hyperalgesic effect in the tail flick
test. In fact, this peptide had the opposite effect: 30 min
and 24 h after administration at a dose of 1.0 mg/kg, it
significantly increased the pain threshold relative to the
control group by 34.0 % and 44.0 %, respectively; and at a
dose of 2.0 mg/kg, it increased the pain threshold by 44.0 %
relative to the control group 24 h after administration. The
development of an analgesic effect at the same time
intervals as the hyperalgesic effect of NGF [17] suggests
that GK-2 may be a functional agonist/antagonist of the
neurotrophin.
GK-6 and GK-2 have no influence on the body weight of rats
Preclinical and clinical trials have shown that NGF
treatment is accompanied by body weight loss [18].
Unlike NGF, daily administration of GK-6 or GK-2 at
the most effective doses (2.0 and 0.5 mg/kg/day,
respectively, i.p.) for 2 weeks did not affect the body
weight of the rats (Fig. 8).
Discussion
Successful attempts to modulate TrkA signaling patterns
by specific ligands have been previously described in the
literature. Saragovi H.U. et al. [19] reported that NGF in
association with anti-NGF antibodies directed against the
C termini of NGF promoted survival but not neurite out-
growth. Mechanism-selective recombinant NGF muteins
that did not support neuritogenesis but maintained the
survival response were designed and characterized by
Maharapta S. et al. [20]. Capsoni S. et al. [21] developed a
“painless” NGF variant by making a point mutation at resi-
due R100, inspired by the human genetic disease HSAN V
(Hereditary Sensory Autonomic Neuropathy Type V).
We found that dimeric dipeptide mimetics designed
based on the NGF loop 1 and 4 β-turn sequences have
different patterns of signal transduction and different
profiles of biological activity. It was revealed by Western
blot assays that the dipeptide mimetic of NGF loop 1
(GK-6) increased the levels of AKT and ERK phosphor-
ylation, whereas the dipeptide mimetic of NGF loop 4
(GK-2) only increased the level of AKT phosphorylation.
These data suggest that GK-6 activates the PI3K/AKT and
MAPK/ERK pathways, whereas GK-2 selectively activates
the PI3K/AKT pathway. Of the two dipeptides, only GK-6
exhibits differentiating activity in PC12 cells. It is known
that cell differentiation through the TRKA receptor is
associated with MAPK/ERK signaling [2]. Thus, the result
that GK-2 does not induce differentiation of PC12 cells
agrees with the result that the dipeptide does not activate
the MAPK/ERK pathway. In addition, we established that
the neuroprotective activity of GK-2 was fully abolished
by a selective inhibitor of PI3K (LY294002) but not a
MAPK kinase inhibitor (PD98059). These results indicate
that GK-2 selectively activates the PI3K/AKT pathway.
The main side effects of NGF are pain and weight loss
[1]. It was shown, using the tail flick test in rats, that GK-6
induced a significant decrease in the pain threshold 1 and
24 h after injection. These time points coincide with the
Fig. 4 GK-6, similarly to NGF, induces the differentiation of PC12 cells,
whereas GK-2 does not. PC12 cells were treated with GK-6 (10-6M), GK-2
(10-5 and 10-8M) or NGF (10-9M) 3 times in 48 h. Cell differentiation was
studied morphometrically. Magnification: 20×. a – untreated control
cells, b – treatment with NGF, c – treatment with GK-6, d – treatment
with GK-2 (10-5 M), e-treatment with GK-2 (10-8M). The bar in the
photomicrographs corresponds to 25 μm
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Fig. 5 Effects of the AKT kinase inhibitor LY294002 on the neuroprotection provided by GK-2 or NGF against H2O2-induced oxidative stress in HT-
22 cells. Hippocampal cells, HT-22, were pre-incubated with LY294002 (100 μM) for 30 min before treatment with GK-2 (10-5M and 10-8M) or NGF
(10-9M). Cell survival after a 30-min exposure to H2O2 was measured by assessment of MTT metabolism. Data are presented as means±SD. * p < 0.05
compared with control, ^ p < 0.05 compared with H2O2 group, # p < 0.05 compared with corresponding H2O2 + GK-2 or NGF + GK-2 (Kruskal–Wallis
ANOVA test with Dunn’s post hoc)
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peaks of NGF-induced hyperalgesia [17]. By contrast, GK-2
did not show any hyperalgesic effect. This result suggests
that the MAPK/ERK pathway is involved in the develop-
ment of hyperalgesia mediated by the TrkA neurotrophin
receptor, whereas the selective activation of the PI3K/AKT
pathway does not cause an increase in pain sensitivity.
Moreover, in our experiments, GK-2 had the opposite ef-
fect: 30 min and 24 h after administration, it increased the
pain threshold relative to both the control group and the
baseline level. Importantly, when administered chronically,
Fig. 6 Effects of the MAPK kinase inhibitor PD98059 on the neuroprotection provided by GK-2 or NGF against H2O2-induced oxidative stress in
HT-22 cells. Hippocampal cells, HT-22, were pre-incubated with LY294002 (100 μM) for 30 min before treatment with GK-2(10-5M and 10-8M) or
NGF (10-9M). Cell survival after a 30-min exposure to H2O2 was measured by assessment of MTT metabolism. Data are presented as means±SD.
* p < 0.05 compared with control, ^ p < 0.05 compared with H2O2 group, # p < 0.05 compared with corresponding H2O2 + GK-2 or NGF + GK-2
(Kruskal–Wallis ANOVA test with Dunn’s post hoc)
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neither dipeptide caused weight loss in rats. For instance,
daily i.p. administration of NGF resulted in significant
weight loss in rats, approximately 15 % compared
with control animals at the 6 day and almost 20 % at
the 30 day of treatment [18]. The fact that GK-6 and
GK-2 have no effect on body weight means that the
activation of pathways other than the PI3K/AKT and
MAPK/ERK pathways is required to produce effects
on body weight.
Conclusions
The current results suggest that the most exposed out-
side fragment of the NGF 4th loop β-turn is the struc-
tural determinant of selective AKT-kinase pathway
activation. Furthermore, our data support the hypoth-
esis that the selective activation of the AKT-kinase
pathway is not associated with hyperalgesia, one of the
main side effects of NGF, whereas the activation of
both the AKT and MAP-kinase pathways generates
nociceptive effects.
The advantageous pharmacological properties of the
dipeptide GK-2 make it a promising NGF-like neuropro-
tective therapeutic agent free of the main side effects of
the neurotrophin.
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Fig. 8 Chronic administration of GK-6 (a) and GK-2 (b) had no
influence on the rats’ body weight. GK-6 (2.0 mg/kg, i.p.) or GK-2
(0.5 mg/kg, i.p.) were injected daily for 14 days. Control animals
received injections of distilled water. The body weight of the rats
was measured every three-four days during the experiment. The
horizontal axis shows the days of the experiment, the vertical axis
shows the average body weight of animals for each group. Data are
presented as means±SEM
Fig. 7 Effect of GK-6 (a) and GK-2 (b) on the pain thresholds in rats
measured by the immersion “tail flick” test. The dipeptide GK-2 was
administered i.p. at doses of 0.5, 1 and 2 mg/kg. Noxious stimuli were
applied by immersing the distal third of each rat's tail in hot water
(55±0.2ºC). Tail flick latency was measured before (baseline level)
and 30, 60 min and 24 h after GK-2 administration. The time intervals
were selected based on data related to NGF-induced hyperalgesia.
Data are presented as means±S.E.M. * p < 0.05, ** p < 0.01, *** p .0.001
compared to the control group (Mann–Whitney U test)
Gudasheva et al. Journal of Biomedical Science  (2015) 22:106 Page 9 of 10
Author details
1Department of Medicinal Chemistry, V.V. Zakusov Institute of Pharmacology,
Baltiyskaya str. 8, 125315 Moscow, Russia. 2Laboratory of Neuroprotective
Pharmacology, V.V. Zakusov Institute of Pharmacology, Baltiyskaya str. 8,
125315 Moscow, Russia. 3Laboratory of Pharmacological Regulation of
Alcohol and Drug Addiction, V.V. Zakusov Institute of Pharmacology,
Baltiyskaya str. 8, 125315 Moscow, Russia. 4Department of Pharmacogenetics,
V.V. Zakusov Institute of Pharmacology, Baltiyskaya str. 8, 125315 Moscow,
Russia.
Received: 10 July 2015 Accepted: 26 September 2015
References
1. Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early
discoveries to the potential clinical use. J Transl Med. 2012;10:1–15.
2. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous
system. Curr Opin Neurobiol. 2000;10:381–91.
3. Obata K, Noguchi K. MAPK activation in nociceptive neurons and pain
hypersensitivity. Life Sci. 2004;74:2643–5263.
4. Longo FM, Massa SM. Small-molecule modulation of neurotrophin
receptors: a strategy for the treatment of neurological disease. Nat Rev
Drug Discov. 2013;12:507–25.
5. Gudasheva TA, Antipova TA, Seredenin SB. Novel low-molecular-weight
mimetics of the nerve growth factor. Dokl Biochem Biophys. 2010;434:262–5.
6. Antipova TA, Gudasheva TA, Seredenin SB. In vitro study of neuroprotective
properties of GK-2, a new original nerve growth factor mimetic. Bull Exp
Biol Med. 2011;150:607–9.
7. Seredenin SB, Silachev DN, Gudasheva TA, Pirogov YA, Isaev NK.
Neuroprotective effect of GK-2, a dipeptide mimetic of nerve growth factor,
during experimental focal ischemia in middle cerebral artery basin. Bull Exp
Biol Med. 2011;151:584–7.
8. Seredenin SB, Romanova GA, Gudasheva TA, Shakova FM, Barskov IV,
Stelmashuk EV, et al. Neuroprotective and antiamnestic effect of nerve
growth factor dipeptide mimetic GK-2 in experimental ischemic infarction
of brain cortex. Bull Exp Biol Med. 2011;150:432–5.
9. Stelmashook EV, Genrikhs EE, Novikova SV, Barskov IV, Gudasheva TA,
Seredenin SB, et al. Behavioral effect of dipeptide NGF mimetic GK-2 in an
in vivo model of rat traumatic brain injury and its neuroprotective and
regenerative properties in vitro. Int J Neurosci. 2015;125:375–9.
10. Banker GA, Cowan WM. Rat hippocampal neurons in dispersed cell culture.
Brain Res. 1997;126:397–42.
11. Senger DL, Campenot RB. Rapid retrograde tyrosine phosphorylation of trkA
and other proteins in rat sympathetic neurons in compartmented cultures.
J Cell Biol. 1997;138:411–21.
12. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific
inhibitor of the activation of mitogen-activated protein kinase kinase in
vitro and in vivo. J Biol Chem. 1995;270:27489–94.
13. Gober MD, Laing JM, Thompson SM, Aurelian L. The HSV vector RR delivers
the anti-apoptotic protein ICP10PK and prevents apoptosis and loss of
function in kainic acid treated organotypic hippocampal cultures through
ERK and AKT activation. Brain Res. 2006;1119:26–39.
14. Tan S, Wood M, Maher P. Oxidative stress induces a form of programmed
cell death with characteristics of both apoptosis and necrosis in neuronal
cells. J Neurochem. 1998;71:95–105.
15. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of
a precise and rapid dye method for measuring cells growth/cell kill.
J Immunol Methods. 1989;119:203–10.
16. Grotto M, Sulman FG. Modified receptacle method for animal
analgesimetry. Arch Int Pharmacodyn Ther. 1967;165:152–9.
17. Hathway GJ, Fitzgerald M. Time course and dose-dependence of nerve growth
factor-induced secondary hyperalgesia in the mouse. J Pain. 2006;7:57–61.
18. Taglialatela G, Foreman PJ, Perez-Polo JR. Effect of a long-term nerve
growth factor treatment on body weight, blood pressure, and serum
corticosterone in rats. Int J Dev Neurosci. 1997;15:703–10.
19. Saragovi HU, Zheng W, Maliartchouk S, DiGugliemo GM, Mawal YR, Kamen A,
et al. A TrkA-selective, fast internalizing nerve growth factor-antibody complex
induces trophic but not neuritogenic signals. J Biol Chem. 1998;273:34933–40.
20. Mahapatra S, Mehta H, Woo SB, Neet KE. Identification of critical residues
within the conserved and specificity patches of nerve growth factor leading
to survival or differentiation. J Biol Chem. 2009;284:33600–13.
21. Capsoni S, Marinelli S, Ceci M, Vignone D, Amato G, Malerba F, et al.
Intranasal “painless” human Nerve Growth Factor slows amyloid
neurodegeneration and prevents memory deficits in App X PS1 mice. PLoS
ONE. 2012;7:e37555. doi:10.1371/journal.pone.0037555.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gudasheva et al. Journal of Biomedical Science  (2015) 22:106 Page 10 of 10
